Press Release: Director's Dealings announcement according to --15a WpHG (the German Securities Trading Act)

BB Biotech AG / Director's Dealings announcement according to --15a WpHG (the German Securities Trading Act) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Details of the person subject to the disclosure requirement Name: Koller, Daniel Person with executive functions: Member of a managing Professional role: body

Designation of the financial instrument ISIN: CH0038389992 Designation: Registered share

Details of the transaction Type of transaction: Buy Date: 26.03.2013 Place (stock exchange): SIX Swiss Exchange Price: 157.10 Currency: CHF Quantity: 200 Business volume: 31420

Details of the company with the publishing obligation: Issuer: BB Biotech AG Vordergasse 3 CH-8200 Schaffhausen Switzerland ISIN: CH0038389992 WKN: 888509

This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB Biotech AG via Globenewswire

HUG#1771891

--- End of Message ---

BB Biotech AG

Vordergasse 3 Schaffhausen Switzerland

WKN: 888509;ISIN: CH0038389992;Index:TecDAX,MIDCAP,Prime All Share,TECH All Share,HDAX;

Listed: Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.bbbiotech.com (END) Dow Jones Newswires

   March 26, 2014 12:50 ET (16:50 GMT)- - 12 50 PM EDT 03-26-14